In conclusion, this study highlights the promising therapeutic potential of combining MDM2 inhibition with STAT3 inhibition in ALL, particularly for p53WT and p53MUT cells with at least partial p53 functionality. This evidence concerns the gene MDM2 and acute lymphoblastic leukemia.